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Although the incidence ofthe use dcalcium channel b ock- 
ers in the treatment of chronic congestive h art failure is not 
entirely known, recent published trials have indicated that 
suchuseisa commonpracticeinboththeUnit.edStatesand 
C8uada.Over3O%ofpatien&em0kdintheStudiesofLeft 
Veutricular Dysfunction (SOLVD) (1) were treated with 
cakiumblockersatthetimeoftheiren&uent.These 
patients, although only mildly symptomatic, had severe 
deprekonoftheirleftventricularsystolicfUndioa,witha 
meaul&ventkuhuejectionfiactionof31%.Possiblymore 
sGkingwasthefhctthatpatieutseurokdina~study 
(2) evaluating the ekct of mikhume on mortality were not 
irdiquentlyonc&iumcbannelblockersatthetimeoftheir 
enrollment @cker M, personal communication). All these 
patientshadtohaveseveresymptomsofheartfirilure(class 
~andIV)tomeetthe~usioncriteriaofthestudyand 
their mean left ventricuh~ ejection Won was 21%. 
Rathale for the use of CalclIuQ ChaMel 
Blockem ln Heart Failure 
Athe~cratio&tktheuseofcalciumchauuel 
blo&elBinthetRatmentafheart&ihueisis 
lIlesedrugsand,inpartic&,thedihydqyrkkdexiva- 
tiveshaveastrongar&riolardilatorelkctaudmay~iu 
IEdllCbd~StelUiCvasculertitallCedthusleft 
venhicular afkload. Dmg~ with ~idar lmnodynamic ef- 
f’ectssuchashydrkiaewhenusedincombh&mwith 
isosorbidedinih&ewereshowntoiuqnxweexercisetoler- 
auceand&ctionfiactionaudreducetheiu&knceofdeath 
in patients with mild to m&rate heart failure 014). Tbe 
lln@ityofa*le~~have~ 
tohaveasubstantialanti-kchemice&ctandmanyofthem 
areusedelkctklyinthetregtment oftheacuteasweuas 
the chronic ischemk syndrome (s7). Because WronaW 
mterydiiseaseisthe~yingcauseofchrwlicheartfaihve 
in6046to7096ofpstieats(1-4),itiswtswprisingthatmaay 
cliuiciansconsidertheuseofcafciumchauuelbkkersin 
such patients a viable thmtic option. The favorable 
eifectOfcalcium~stsOaleftVelltIicular~ 
mayleadto~of&stolicdysfuractioaO,~ 
isfilllpOaant~SedheliItfhilureSymp0oms.~~ 
pitiemwithdocumentedleffven~s~dysfunc- 
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tion (9). In additbn, the prevention of calcium ion entry into ‘k#r 1. Episodes of Hospitals and Increase in Diuretic 
nmca&l cells has been sbwn to prevent the development Divgs fcr Worsen@ Congestive Heart Failure 
o&ohol-media&dcardiacdysfu&tioninhamstermyocar- 
dium and could have a similar protective et&t in humans 
(10). 
R&ats (no.) 
lnacarcill CHF 
IXlllWiC E16sodes 
-Ihatmellt 
. . 
liomabdi Dose Total (00.) 
Nifi!d#h 
B- d Ilitiedipiae's pwuful vasodilator eiTect, a 
strweinteresthas~shownoverthelastdecadeinusing 
thisdrugasanunMingagentinthetreatmentofheart 
faihuw. Several investigatom (1 I-IS) nported ImmdYti 
improvement atter single-dose administration of tlifedipille 
given either orally or sublingually in relatively small ttroups 
uf patients with acute or chronic heatt failure. The mqjority 
dthesedatawereqortedasameangrouprespon~~d 
demonstrated a reduction i systemic vasc& resistance 
and mean bloud pressure, with augmentation of cardiac 
outputenJs~~volume.Lackofc~inbotbrigbtand 
IeII ven&dar Iillipg pressures in most studiis (16) veriiied 
the ptedominant rteriolar nd negtl@ble v nous effects of 
thea 
Although t e initial experience with the use ofnifedipine 
in heart failure led to the conch&m by some investigators 
(11-15) thatthene@veiwtropice&ctofnifedipinemaybe 
oBetbyitsvasodilatoreBbct,tbrtherevaiuationin~r 
groups of patients demonstrated the clmical relevance of the 
negative inot@c e&t of the drug (17-19). Cm of 
niMipine with nitrop~aside (20) demonstrated a smaller 
auguentationincardiacoutputanda~rdecreasein 
systemic blood pressure with niMipine despite a similar 
reduction i  systemic vascular resistance. These hem+ 
namic haages wem associated with a decrease in the first 
derivative ofleft venuicular p essure (dP/dt) with nifedipine 
(21). Siiy, a comparison of changes in hemudynamic 
indexes of left ventticular systolic fuuction after a similar 
redu&n in systemic vascular resistance with hydrala&e 
and nifedipine in the same patients with heart failure (18) 
resulted in a si@icantly smaller augmentation of stroke 
vdume,caldiacoutputandleftventricuhlrstrokework 
index, with q i&dipine deuumstrating he clinical relevance 
of its ne@ive inutropic effect. Further evaluation f the 
hemudynamicprofdeofnifediphteintwolargeseriesof 
patients (19-22) showed acute hemodynamic and clinical 
. . 
~efferasingledoseof2Oto50mgofthedrugin 
19% and 29% of the patients, respectively. Hemodynamic 
req=secouklnotbepredictedfiombaselinehemodynamic 
data nd left ventricular ejection &action (19). However, a 
strons &tion was fwnd between an untbvorable acute 
kmodynamic response to nifedipine, and long-term ortal- 
ity data (22) supported the hypothesis that hemdynamic . . 
detenoratNIll* nk@ine administtation is more likely to 
occur in patients with mUn severe heart ibikt~. 
The km@erm e&t ofnifedipine in pntieuts with heart 
failure due to left ventricular systolic dysfuncuou was ~6 
CentlY evaluated in two nmdomii trials. In the first study, 
NIF (n = 21) P 3 8 !Jf 
lSDN(n=20) 0 3 3 3 
NIFtISDN 6* 2 8 2lH 
(lJ=23) 
‘p c a03 WBUS isoschde tlinhte (ISDNI. tp C 0.09 versus howbide 
dhdtnte, b c 0,atol versus isosorbide initrate; Op < 0.001 versus nikdipine 
(NIP). CHP = amgdve hmrl fdm. Rcpmduced. with permkion oftk 
Amdcao Hmrl As!5&th. Inc.. fhm mayam et al. (24). 
Agostoni et al. (23) compared in a double-blind cmsover 
design, the eifect of captopril(50 mg three times daily) and 
nifedipine (20 mg three times daily) given for 8 weeks each in 
18 patients with died cardiomyopathy w o were optimally 
treated with diiis and diuretic drugs. This study demon- 
strated symptomatic and fimctional improvement a d en- 
hancement of exercise tolerance with captopril but not with 
nifedipine. Although inthe short-term, nifedipine r sulted in 
 reduction i systemic vascular resistance that led to 
augmentation of cardiac output and a small reduction in left 
ventricular filling pressure, after prolonged treatment, car- 
diac output returned tobaseline values and pulmonary artery 
wedge pressure increased substantially. These changes were 
accompanied by worsening heart tXlure symptoms in ome 
ptients. In a second study, Elkayam et al. (24) compated 
the ctfect of long-term administration (8 weeks) of isosorbide 
dinitrate (40 nt9 four times daily), nifedipine (20 mg four 
times daily) and their combination n patients with mild to 
moderate chronic heart faihue. This study demonstrated a 
s@iicantly higher incidence of heart failure worsening, 
necessitating e hanced diuretic therapy or hospitalization, 
orboth,in~i~~treatedwithnaklipineeitheraloneorin 
combination with isosorbide inittute (I’able 1). Hospitalixa- 
ti n was requited by 24% of patients during nilbdipine 
therapy, by 26% during nifedipine4sosorbide dinitrate com- 
bination therapy incomparison with 0% during isosorbide 
dinitrate herapy alone. The total number of episodes of
worsenin chronic heart failure was 9 during n&dipine 
therapy, 3 during isosorbide initrate herapy and 21 during 
nifedipiue4sosorbide diuiuate combination therapy. Rema- 
tute diiontinuation f drug administration because ofciii 
icaldeteriorationorothersideeffectsoccur&in29%of 
patients duripg nifedipine therapy, in3% during isosorbide 
dinitrate hetapy (p= 0.05 vs. nifedipine) and in 19% during 
combination therapy. 
These unfavorable results associated with the use of 
nifedipine in patients with chronic heart faillue led to at- 
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E&we 1. Cumulative rate uf llrst recurrent cardiac events on 
diltiazem and pkebu in patients with and without chest X-ray 
evidence of pulmonary congestion. Reproduced. with permission, 
from The Multicenter Diltiazem Postinfarction Trial Research 
Group (29). 
tempts to use diltiazem, a first-generation calcium antagonist 
with a smaller my&al depressant effect (25,2!i). Hemo- 
dynamic evaluation of this agent in patients with severe 
chronic heart failure demonstrated only little hemadynamic 
effect and a sigoiitly lesser incidence of hemodynamic 
and symptomatic deterioration compared with results with 
nifedipine. However, occasional deterioration bserved in 
these studies (25-27) was the first indication of the potential 
hazardofthisdrugasweU.In198!J,FiiUaetal.(28) 
repurted on a prospective study using diitiazem (60 to 90 mg 
three times daily) in 22 patients with dilated ca&myopathy 
in addition to conventional therapy with diitalis. diuretic 
drugs and va&ikrs and compared their outcome with 
histokal control data from 25 patients with C~IK& heart 
feilure receiving conventional therapy alone. The mean 
survival of the control group was 29 months, whereas no 
patient reated with diltiazem died over a mean follow-up 
period of 15.4 months. In addition, a significant improve 
ment iu clinical status and left ventrkular function was 
reporkd in the diltiazem group but not in the control group. 
Although the investigators suggested a beneficial effect of 
adjunctive diltiazem treatment in dilated cardiomyopathy, 
theuncontrolleddesigaafthetrialandthesmallnumberof 
patients in both arms everely limited both the scientific and 
the clinical v* of the study. 
The Multicenter DilWm PostSarction Trial (29) pro- 
vided usefid information regardii the long-term use of this 
drug in patieots with clinkal heart fkihue (Fig. 1). ‘Ilk study 
evahmted the e&ct of diltiazem (240 m&lay) on mortality 
I@IIE 2. Relation between the percent of patients recei* dilt- 
iazem(D,blPcLbrrs)orplacebo(P,WfLcdbaP)developiqgnewor 
worsened congestive heart failure (0 during lon@xm folluw- 
up. The number of patients with congestive heart failme is shuwn as 
the numerator and the tutal number in each @tiun fraction (EF) 
group is shown as the deucuninatur above each bar. Repruduced, 
with permission. of the American Heart Association. Inc., frum 
Goldstein et al. (30). 
and reinfarction i 1.237 patients 3to 15 days atbx the date 
of onset of myocardkl infarction and compared it with the 
elkct of placebo in 1,232 similar patients. In 490 patients 
with evidence of pulmonary congestion on the chest roent- 
genogmm, diltiazem was associated with an &eased num- 
ber of cardiac events. A similar pattern was observed with 
respect to dep~ssed mdionuclide qjection 6action and an- 
te.xWeral Q wave infarction. In I.909 patients without 
pulmonary comstion, diltiazem was associakd with a 
smaller number of cardiac events. In a further evaluatkm of 
the development of congestive htart failure in this study, 
Goldstein et al. (30) showed that patients with puWmary 
congestion, anterolateral Q wave i&r&m or reduced ejec- 
tion fraction (~40%) at baseline were more likely to develop 
chronic heart feilure during follow-up than were patients 
without hese makers of left ventricular dysfunckm. In 
addition, the diltiazem-associated increased liilihoai of 
developing chronic heart failure was inversely related to the 
degree of left ventricular dysfunction (Fig. 2). This trial 
~nch~~My demonstrated hehazanl involved in the use of 
diltiaxm in patients with chronic heart failure due to left 
ventkular systolii dysfunction. 
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TheexperiencerelatedtotheuseofvempamWheart 
failureislimitedbecauseofthekaownnegative~c 
efkctofthedrugandthewamingbythemanufutuer 
~theriskofdevelopingheartfail~(31).Ine 
smaUstudy,FerlinxandGallo(32)followedup10patients 
withheartEhuewhoinitiaUydemonstratedacutehemody- 
aamic immt after w administration. How- 
ever, durillg the follow4lp eriod, fkur patients demon- 
. . 
-~tong-bermvereoamil 
~.TheDanishstudyouheeffectofvemp&lon 
deathor&kction(33)insurvivorsofacatemyocardM 
il&tioUfUayprovidesOmeiadiredbUtUsefllliadprmation 
Nqudil@theeffiectofthiscelcium~tinpatients 
WithChroniclWtfaihue.ThiSllllll~dOUb~, 
plaCc~study~vaapamil(l2o~thrcc 
timesdaily)vefsusplaceboinp#&lts7to15daysafter 
theirmyoca&linfar&n.Atameanfi4low-uptimeof 
16months~hadcausedasi@kantreduc& 
ofaImutyandcaldiaceventsin~withoutbutaot 
iopatientswithchronicheartGhue(Fig.3).Theexcl~ 
crikliatothisstudy~healtfaihlrenot~lled 
with furoaemide (5160 mgklay), which re!&ed in ex- 
chlsionof1396ofthelYatieats.Althovgbtheiavestigators 
coachldedthatin~too,verapamilhadao 
detrimentalektiapatientswithheartfail~,onecumot 
excludethepossib@thatthefivofableektof~ 
nportedbWkntswithoutheartfsilunwas~bythe 
q Wdepm=ateikctdthednylin*with 
heart f&we. 
Cause8 of Umfhvorable Eibct8 of Calcium 
-Blockers 
In summary, available inf~tion demoastmtes a risk 
ZttWCkdWiththC~OfW-MCalciumantego- 
nistsinpatientswithheartfkil~duetoleftventrMar 
systolic dysfuction. These drugs have been shown to cause 
hemodynamicaswellas&icaldeteriorakminawnsider- 
ableaumberofpatientsaadto iWeasetheincidenceof 
cardiaceventsinsurvivalaftermyoca&linfarctionwith 
cliaiu~Uydocumented he&M=. 
IstheetiologyofchKmicheartfaihlreimpoltaatiathe 
response ofpatients o a calcium chaanel blocker? Con- 
trolledstadies~the~of~chlm~ 
blackers as antiangkl agents have usually excluded pa- 
tients with chronic heart fake. However, u&vomble 
&CCtSOfthC!dNgSinpUiCll~WitllChIUmiChClNtM~ 
after myoca&l infarction (24,3033) and ia patknts with 
chronicheartfaihweduetowrooaryarterydisease(22~) 
s-t that calcium atWgoaists may not be sak, even in 
patientswithchronicheartfaihueandischemicheartdis- 
ease. 
The mechanism respon&le for the clinical deterioration 
assoc&dwithcalcium~stsinheartfaihueisprob 
ably multifactorial. Immediate h modynamic deterionttion 
reported by some invest@tofs (19~22J4,2!5) is most likely 
duetothenegativeiwtropiceffectofthesedrugs.Reporkd 
. . 
deamatm despite hemodynamic improvement 
EJ5) may suggest activation f untkvorable a urohor- 
moklmechaaismsasacauseofthede&oratkm(36). 
Activation of the sympathetk nervous system, the renin- . 
aagu~&& system and vasopressia have been documented 
with nifkdipine (21,37) aad nisoldipioe (35), a second- 
generation dihydnqyridine. B cause there is no evkkce 
forreducioninrenal bloodlIowwithcalciumaata@stsia 
~heartfaihl=O,~ krea!Seinreninlevelis 
probablytheresultofbWcadedtheiahibitoryeBectof 
calciumonreninprodu&n(39).AthirdpotentSmecha- 
nismf rclhdcaldetek&mwithcalcium~tsin 
chronicheartfail~maybeanincreaseinbloodvolumeas 
shownby- inueaseinbodyweight(34)anddecreasein 
hemat&t(27,34).Aakeaseinbloodvolumemaybedue 
to~waterexcretion(35)andmaybethecauseofa 
&stWialinueaseinpubnonqarterywedgeprcssu~ 
desUibedbyAgo!Mdetei.(23)dWhlghWlg-t~trerrtment 
with n&dip&. 
~A- 
lnauattemptto~vethesafetyofcal~chaMel 
bbuckhgdNgsinpatientswilhchronicheartfail~,the 
Mlowhg tippmds have been sugfgested (36): 1) use of 
second~calciamaa@or&sthathavelessdhect 
myocardMe&ct;2)combi&gcalchunchannelb~ 
withconvertkenxvmeinhibitktoureventneuohor- 
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ers that exert thorable neurohonnonal effects. Some cur- 
rently available information may help to assess the validity 
of these approaches. Batjon et al. (35) used nisoklipine, a 
second-generation calcium channel bktcker with potent va- 
sodilator e&cts and only mild negative inotropic e&cts (40), 
and reported the development of puhnonary edema inseven 
patients during a 2-month follow-up eriod. Fekxlipine, 
another cak5um antagonist of dihydropyridine group, is 
@to have negligiile negativeinotmpice&ctsand 
high selectivity to smooth muscle (41). Its use was reported 
by Dunsehnan et al. (42), who found in a doubleblind study, 
an improvement in aerobic apacity and exercise duration 
after 16 weeks of enalapril(10 mg twice daily) therapy in I 1 
patients with class III congestive h art failure but not in 9 
patients receiving felodipine (10 mg twice daily). In a pre 
hminary study, Gheor@ade etal. (43) evaluated the e&t 
of nicardipine, aaother second-generation calcium antago- 
nist, in patients with moderate to severe beart failure. To 
evaluate he hypothesis that calcium chanuel b ockade may 
benefit patients with chronic heart failure when used con- 
comitantIy with angiotensin-converting nzyme inhibitors, 
which may prevent s imulation f neuroendocrine systems, 
all patients were concomitantly t eated with captopril. De- 
spite this a@nctive therapy, the use of nicardiphle (20 to 
30 mg every 8 h) over 4 months resulted inworsen& of 
chronic heart faihue in 60% of patients receiving icardipine 
and 20% of patients receiving placebo (p= 0.06). Concom- 
itant use of captopril also did not prevent neurohormonai 
activation media&l by nicardipine (r nin ind from 7 f 
6 to 22 f 28 @ml per h, p < 0.05). The studies just 
mentioned suggest that he use of second-generation calcium 
channel b ockers with reported selectivity to smooth muscle 
and the concomitant use of angiotensin-converting nzyme 
inhibitors does not provide a simple solution to lack of 
eBcacy or the deleterious e&cts of the calcium channel 
blockers inpatients with chronic heart Mure. 
Will the use of calcium antagonists with favorable effects 
on neurohormonal systems be bene6cial fmthe treatment of 
chronicheartGhue?A positiveanswertothisquestionmay 
be suggested by the rest&s of a recently completed multi- 
center study (44) of atulodipine in chronic heart faihue. In 
thisstudy,N36patientswithciassIIandIIIchKmicheaIt 
faihue (left ventricular ejection fraction <40%) were ran- 
domizedto a WithamMpine, asecond-generation 
dihydropyridine calcium chanoel b ocker, or to placebo and 
were followed up tir 4 months. AU patients received a 
diutetic drug and digitalis and 80% were also treated with 
at@otensin-couvertingenzymeinhibition. Theresultsofthis 
trial demonstrated a sign&antly larger improvement in 
exercisetime(62+ 17vs.22* 13s,p<O.O5)andreduction 
in chronic heart faihue symptoms (55% vs. 29%, p c 0.05) 
with amlodipii than with placebo. These favorable changes 
wereassociatedwithasig&antrwductionintheserum 
. 
w level. 
Al- the results of this study are encomnging and 
may extend the therapeutic bridge of calcium antagonisfi 
(45) far enou@ to provide treatment benefit topatients with 
chronic heart failure, consistent evidence fop deleterious 
effects ofcalcium channel bluckade in such parkuts suggests 
the need for caution. Fortunately, more infonnatkm is likely 
to become available r gard& the safety and e&acy of 
calcium channel b ocking a ents inchronic heart failure. The 
ongoing Vasodilators in Heart Failure Trial (V-HeFT III) is 
evaluating the etfect offelodipiae w with placebo on 
morbidity and mortality ia patients with mikl to moderate 
chronic heart failure treated with diuretic drugs and 
angiotensin-converting nzyme inhibitors with and without 
digoxin. In add&ion, the ongoing Prospective Randomized 
Amlodipine Survival Evaluation (PRAISE) is studying the 
e&d of ambdipine versus placebo on survival inpatients 
with class III and IV chronic heart failure who ate concom- 
itantly treated with augiotensin-converting nzyme inhibi- 
tors. 
These studies are likely to provide the information 
needed to determine whether there is a de for calcium 
channel b ockade inthe treatment of chronic heart failure 
due to left ventricular systolic dysfunction. 
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